99
Participants
Start Date
November 6, 2020
Primary Completion Date
November 30, 2026
Study Completion Date
May 30, 2030
Alectinib
Participants will receive oral alectinib twice per day (BID).
Entrectinib
Participants will receive oral entrectinib daily.
Vemurafenib
Participants will receive oral vemurafenib BID.
Cobimetinib
Participants will receive oral cobimetinib daily.
Pralsetinib
Participants will receive oral pralsetinib daily.
Atezolizumab
Atezolizumab will be administered by intravenous (IV) infusion.
SBRT
Participants will receive SBRT given concurrently, starting with the first dose of atezolizumab.
Resection
Participants will receive surgical resection of the primary tumor along with selected lymph nodes per SOC.
Chemotherapy
Participants will receive SOC chemotherapy as determined by the treating physician.
Divarasib
Participants in the KRAS G12C cohort will receive oral divarasib for approximately 8 weeks until the day before surgery as neoadjuvant therapy up to 3 years as adjuvant therapy.
RECRUITING
Laura and ISAAC Perlmutter Cancer Center at NYU Langone., New York
RECRUITING
Columbia University Medical Center, New York
RECRUITING
Memorial Sloan Kettering Cancer Center, New York
COMPLETED
AHN Cancer Institute ? Allegheny General Hospital, Pittsburgh
RECRUITING
MedStar Georgetown University Hospital (Lombardi Comprehensive Cancer Center), Washington D.C.
RECRUITING
Virginia Cancer Specialists (Fairfax) - USOR, Fairfax
RECRUITING
Moffitt Cancer Center, Tampa
WITHDRAWN
Tennessee Oncology - Nashville, Nashville
RECRUITING
Baptist Clinical Research Institute, Memphis
RECRUITING
Ohio State University, Columbus
WITHDRAWN
University Hospitals Cleveland Medical Center, Cleveland
RECRUITING
University of Michigan, Ann Arbor
WITHDRAWN
Karmanos Cancer Institute - Farmington Hills/Weisberg Cancer Treatment Center, Farmington Hills
RECRUITING
Mayo Clinic, Rochester
RECRUITING
Northwestern Medicine Cancer Center Kishwaukee, DeKalb
RECRUITING
Northwestern Medicine Cancer Center Delnor, Geneva
RECRUITING
Northwestern Medicine Cancer Center Warrenville, Warrenville
RECRUITING
Northwestern University, Chicago
RECRUITING
Siteman Cancer Center - Washington University Medical Campus, St Louis
RECRUITING
Ellis Fischel Cancer Center, Columbia
WITHDRAWN
Kelsey Seybold Clnic, Houston
WITHDRAWN
Baylor College of Medicine, Houston
WITHDRAWN
Lumi Research, Kingwood
WITHDRAWN
University of Colorado - Anschutz Medical Campus (University of Colorado Health Sciences Center), Aurora
WITHDRAWN
USC Norris Cancer Center, Los Angeles
WITHDRAWN
Cedars-Sinai Medical Center, Los Angeles
RECRUITING
University of California Los Angeles - Jonsson Comprehensive Cancer Center, Los Angeles
WITHDRAWN
City of Hope Comprehensive Cancer Center, Duarte
WITHDRAWN
City of Hope - Orange County Lennar Foundation Cancer Center, Irvine
RECRUITING
The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange, Orange
WITHDRAWN
UCSF Helen Diller Family CCC, San Francisco
RECRUITING
UC Davis Comprehensive Cancer Center, Sacramento
WITHDRAWN
Seattle Cancer Care Alliance, Seattle
RECRUITING
Yale Cancer Center, New Haven
WITHDRAWN
Boston Medical Center, Boston
RECRUITING
Dana-Farber Cancer Institute, Boston
RECRUITING
Dartmouth Hitchcock Medical Center, Lebanon
RECRUITING
University of Texas MD Anderson Cancer Center, Houston
Lead Sponsor
Genentech, Inc.
INDUSTRY